The rapidly evolving state of gene therapy

Area of Science:

• Biotechnology
• Genetics
• Medical Science

Background:

• Gene therapy has transitioned from a theoretical concept to a practical therapeutic tool.
• Recent regulatory approvals in the US and Europe signify the maturation of gene therapy.
• The field has seen significant advancements in the past decade.

Purpose of the Study:

• To provide an overview of the current state of gene therapy.
• To discuss various gene therapy vector platforms.
• To review the types of gene therapies currently available.

Main Methods:

• Review of recently approved gene therapy products.
• Discussion of different gene therapy vector systems (e.g., viral vectors like rAAV, gammaretrovirus, lentivirus).
• Analysis of ex vivo and in vivo gene therapy approaches.

Main Results:

• Approved gene therapies include Luxturna (rAAV for Leber congenital amaurosis 2), Glybera (rAAV for lipoprotein lipase deficiency), Strimvelis (gammaretrovirus for ADA-SCID), and Kymriah (lentivirus for CAR-T in ALL).
• Multiple vector platforms are utilized for different genetic disorders.
• The landscape of gene therapy is rapidly expanding with ongoing research and development.

Conclusions:

• Gene therapy is a viable clinical option for monogenic and genetically defined diseases.
• The continued evolution of vector technology and therapeutic approaches promises further clinical applications.
• The field is poised for additional product approvals as it matures.